Geographic atrophy is a growing worldwide health issue, with approximately 8 million patients impacted, according to a ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation's PRIMA implant is the first treatment in clinical trials to successfully restore functional ...

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that results in progressive and irreversible vision loss, particularly in older adults. It occurs due to the ...

Geographic atrophy (GA), the late stage of age-related macular degeneration (AMD), may lead to vision loss. Here’s what to expect as the condition progresses. About 1 million people in the United ...

Avacincaptad pegol (Zimura, IVERIC bio) slows the progression of geographic atrophy, results from a phase 3 clinical trial show, giving hope that there will soon be an approved treatment for one of ...

What is IZERVAY™?IZERVAY (avacincaptad pegol intravitreal solution) is a prescription eye injection, used to treat geographic atrophy (GA), the advanced form of dry age-related macular degeneration ...

Mary is the bedrock of her family. “She’s the one we all go to,” says her son Eric. “She’s selfless, extremely sweet, very personable—but she can also be very feisty.” So when she returned from an eye ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...